On May 27, Eisai (ESAIY) and Biogen (BIIB) announced that the Ministry of Food and Drug Safety, or MFDS, in South Korea has approved humanized anti-soluble aggregated amyloid-beta monoclonal antibody “Leqembi,” or lecanemab, for treatment in adult patients with mild cognitive impairment due to Alzheimer’s disease, or AD, or mild AD. Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. In South Korea, Eisai Korea Inc. will distribute the product and conduct information provision activities.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biotech Alert: Searches spiking for these stocks today
- Biogen acquiring HI-Bio in increased immunology focus, says William Blair
- Biogen acquisition has positive read for IGM Biosciences, says RBC Capital
- Biogen deal for HI-Bio ‘makes sense,’ says Stifel
- Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences